SCHEMBL361765

SCHEMBL361765

O=C(O)c1ccc(-c2ccc(F)cc2)[nH]c1=O

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.72
ALDH1A1 P00352 3/20 0.65
GAA P10253 3/20 0.65
SMN1; SMN2 Q16637 1/20 0.65
RXFP1 Q9HBX9 1/20 0.65
ERCC1 P07992 1/20 0.62
ERCC4 Q92889 1/20 0.62
BCL2L1 Q07817 1/20 0.44
BAD Q92934 1/20 0.44
PTPN1 P18031 1/20 0.43
PTPN11 Q06124 1/20 0.43
HPGD P15428 2/20 0.41
USP2 O75604 1/20 0.41
HSD17B10 Q99714 1/20 0.41
MAPT P10636 3/20 0.41
GSK3B P49841 1/20 0.40
HTT P42858 1/20 0.39
KMT2A Q03164 1/20 0.39
TNKS O95271 1/20 0.39
GCGR P47871 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25148579 0.85 KDM4E (0.65) KDM4EALDH1A1GAASMN1; SMN2RXFP1
SCHEMBL2589472 0.85 ERCC1 (0.60) KDM4EALDH1A1GAASMN1; SMN2RXFP1
SCHEMBL4429820 0.84 KDM4E (0.93) KDM4EALDH1A1GAASMN1; SMN2RXFP1
SCHEMBL4074628 0.84 KDM4E (1.00) KDM4EALDH1A1GAASMN1; SMN2RXFP1
SCHEMBL25149281 0.83 KDM4E (0.72) KDM4EALDH1A1GAASMN1; SMN2RXFP1
SCHEMBL17844580 0.83 KDM4E (0.72) KDM4EALDH1A1GAASMN1; SMN2RXFP1
SCHEMBL11111623 0.83 KDM4E (0.72) KDM4EALDH1A1GAASMN1; SMN2RXFP1
SCHEMBL14931973 0.82 KDM4E (0.66) KDM4EALDH1A1GAASMN1; SMN2RXFP1
SCHEMBL25148574 0.82 KDM4E (0.61) KDM4EALDH1A1GAASMN1; SMN2RXFP1
SCHEMBL1547993 0.81 KDM4E (0.55) KDM4EALDH1A1GAASMN1; SMN2RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2867223-A1 NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS Betta Pharmaceuticals Co., Ltd. (CN) 2015-05-06 EP claimed
WO-2014000713-A1 NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS ZHEJIANG BETA PHARMA INCORPORATION (CN) 2014-01-03 WO claimed
EP-2593462-A1 NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS Zhejiang Beta Pharma Inc. (CN) 2013-05-22 EP claimed
WO-2012006960-A1 NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS ZHEJIANG BETA PHARMA INC. (CN) 2012-01-19 WO claimed
WO-2010077530-A1 C-RING MODIFIED TRICYCLIC BENZONAPHTHIRIDINONE PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2010-07-08 WO claimed
EP-4178953-A1 DERIVATIVES OF 2-OXO-N-(4-(PYRIMIDIN-4-YLOXY/THIO)PHENYL)-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE FOR USE AS PROTEIN KINASE INHIBITORS FOR THERAPY Aucentra Therapeutics Pty Ltd (AU) 2023-05-17 EP disclosed
WO-2023062575-A1 CYCLIC VINYL SULFONE COMPOUNDS AS WRN INHIBITORS IDEAYA BIOSCIENCES, INC. (US) 2023-04-20 WO disclosed
WO-2022006638-A1 DERIVATIVES OF 2-OXO-N-(4-(PYRIMIDIN-4-YLOXY/THIO)PHENYL)-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE FOR USE AS PROTEIN KINASE INHIBITORS FOR THERAPY AUCENTRA THERAPEUTICS PTY LTD (AU) 2022-01-13 WO disclosed
EP-3762392-A1 THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Wellmarker Bio Co., Ltd. (KR) 2021-01-13 EP disclosed
WO-2019182274-A1 THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME WELLMARKER BIO CO., LTD. (KR) 2019-09-26 WO disclosed
EP-3436461-A1 PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS Incyte Corporation (US) 2019-02-06 EP disclosed
WO-2017172596-A1 PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS INCYTE CORPORATION (US) 2017-10-05 WO disclosed
WO-2007033196-A1 MET KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-03-22 WO disclosed
EP-1761268-A2 PYRROLOTRIAZINE KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2007-03-14 EP disclosed
EP-1742948-A2 BICYCLIC HETEROCYCLES AS KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2007-01-17 EP disclosed
EP-1737451-A2 MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2007-01-03 EP disclosed
WO-2006004636-A2 FUSED HETEROCYCLIC KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2006-01-12 WO disclosed
WO-2006004833-A2 PYRROLOTRIAZINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2006-01-12 WO disclosed
WO-2005117867-A2 MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2005-12-15 WO disclosed
WO-2005116028-A2 BICYCLIC HETEROCYCLES AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2005-12-08 WO disclosed